N6-methyladenosine with immune infiltration and PD-L1 in hepatocellular carcinoma: novel perspective to personalized diagnosis and treatment

被引:11
|
作者
Shi, Yanlong [1 ]
Wang, Yizhu [1 ]
Zhang, Wenning [1 ]
Niu, Kaiyi [1 ]
Mao, Xinyu [1 ]
Feng, Kun [1 ]
Zhang, Yewei [1 ]
机构
[1] Nanjing Med Univ, Affiliated Hosp 2, Hepatopancreatobiliary Ctr, Nanjing, Jiangsu, Peoples R China
来源
FRONTIERS IN ENDOCRINOLOGY | 2023年 / 14卷
基金
中国国家自然科学基金;
关键词
N6-methyladenosine; hnRNPC; PD-L1; hepatocellular carcinoma; prognosis; immune infiltration; immunotherapy; RNA; M(6)A; TRANSCRIPTOME; ROLES;
D O I
10.3389/fendo.2023.1153802
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundIncreasing evidence elucidated N6-methyladenosine (m6A) dysregulation participated in regulating RNA maturation, stability, and translation. This study aimed to demystify the crosstalk between m6A regulators and the immune microenvironment, providing a potential therapeutic target for patients with hepatocellular carcinoma (HCC). MethodsTotals of 371 HCC and 50 normal patients were included in this study. GSE121248 and GSE40367 datasets were used to validate the expression of HNRNPC. The R package "ConsensusClusterPlus" was performed to screen consensus clustering types based on the expression of m6A regulators in HCC. The R package "pheatmap", "immunedeconv", "survival", "survminer" and "RMS" were applied to investigate the expression, immunity, overall survival, and clinical application in different clusters and expression groups. Comprehensive analysis of HNRNPC in pan-cancer was conducted by TIMER2 database. Besides, HNRNPC mRNA and protein expression were verified by qRT-PCR and immunohistochemistry analysis. ResultsMost of m6A regulators were over-expressed excerpt for ZC3H13 in HCC. Three independent clusters were screened based on m6A regulators expression, and the cluster 2 had a favorable prognosis in HCC. Then, the cluster 2 was positively expression in macrophage, hematopoietic stem cell, endothelial cell, and stroma score, while negatively in T cell CD4(+) memory and mast cell. We identified HNRNPC was an independent prognostic factor in HCC, and nomogram performed superior application value for clinical decision making. Moreover, PD-L1 was significantly up-regulated in HCC tissues, cluster 1, and cluster 3, and we found PD-L1 expression was positively correlated with HNRNPC. Patients with HCC in high-expression groups was associated with tumor-promoting cells. Besides, HNRNPC was correlated with prognosis, TMB, and immune checkpoints in cancers. Particularly, the experiments confirmed that HNRNPC was positively expression in HCC cells and tissues. ConclusionThe m6A regulators play irreplaceable roles in prognosis and immune infiltration in HCC, and the relationship of HNRNPC and PD-L1 possesses a promising direction for therapeutic targets of immunotherapy response. Exploration of m6A regulators pattern could be build the prognostic stratification of individual patients and move toward to personalized treatment.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
    Li, Qian
    Han, Jingjing
    Yang, Yonglin
    Chen, Yu
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [32] N6-Methyladenosine Modification and Prognostic Analysis of UBE2K in Hepatocellular Carcinoma: A Potential Target
    Guo, Jinhui
    Zhao, Jie
    CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, 2023, 33 (08):
  • [33] Mechanisms of RNA N6-Methyladenosine in Hepatocellular Carcinoma: From the Perspectives of Etiology
    Lu, Jiahua
    Qian, Junjie
    Yin, Shengyong
    Zhou, Lin
    Zheng, Shusen
    Zhang, Wu
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [34] Effect of N6-methyladenosine methylation-related gene signature for predicting the prognosis of hepatocellular carcinoma patients
    Zheng, Xinyu
    Zhang, Yingyue
    Wang, Yun
    He, Zijing
    Zhang, Qiang
    Ren, Dapeng
    Yan, Xiao
    Yuan, Xiao
    FRONTIERS IN SURGERY, 2023, 10
  • [35] The regulation of N6-methyladenosine modification in PD-L1-induced anti-tumor immunity
    Yu, Wei
    Lin, Jinti
    Yu, Tao
    Lou, Jianan
    Qian, Chao
    Xu, Ankai
    Liu, Bing
    Tao, Huimin
    Jin, Libin
    IMMUNOLOGY AND CELL BIOLOGY, 2023, 101 (03) : 204 - 215
  • [36] N6-Methyladenosine RNA Modification in the Tumor Immune Microenvironment: Novel Implications for Immunotherapy
    Guo, Liting
    Yang, Hui
    Zhou, Chenfei
    Shi, Yan
    Huang, Lei
    Zhang, Jun
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [37] N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma
    Cai, Jihao
    Zhou, Minglei
    Xu, Jianxin
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2021, 19 (01)
  • [38] Relationship Between PD-L1 Expression and CD8+ T-cell Immune Responses in Hepatocellular Carcinoma
    Huang, Chun-yu
    Wang, Ying
    Luo, Guang-yu
    Han, Feng
    Li, Yong-qiang
    Zhou, Zhong-guo
    Xu, Guo-liang
    JOURNAL OF IMMUNOTHERAPY, 2017, 40 (09) : 323 - 333
  • [39] N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma
    Jihao Cai
    Minglei Zhou
    Jianxin Xu
    World Journal of Surgical Oncology, 19
  • [40] PD-L1 expression in hepatocellular carcinoma
    Kanda, Hiroaki
    Mahmut, Yasin
    Shigematsu, Yasuyuki
    Sugiura, Yoshiya
    Yamamoto, Noriko
    Ishikawa, Yuichi
    CANCER SCIENCE, 2018, 109 : 1123 - 1123